by tim » Fri Jul 04, 2025 9:25 am
https://jonfleetwood.substack.com/p/bir ... accination
Bird Flu ‘Outbreak’ Follows Vaccination in Same South African City—Was It the Virus or the Vaccine?
Are governments faking disease outbreaks with Trojan Horse vaccines?
Summary
June 6, 2025: South Africa begins mass poultry vaccination using three approved H5 vaccines: Vectormune® H5, Boehringer Ingelheim B.E.S.T H5, and Zoetis HPAI H5N1—all containing detectable viral material.
June 30, 2025: Astral Foods receives permit to vaccinate chickens in Mpumalanga with inactivated H5N2 virus.
July 1, 2025: Bird flu is “detected” in two Mpumalanga poultry farms.
PCR testing is a standard method used by South African veterinary authorities to detect purported avian influenza strains.
All three vaccines registered for use in South Africa contain viral RNA or DNA that can be detected by PCR.
Key question: Did officials detect a genuine H5N1 infection—or simply pick up vaccine-derived RNA and reclassify it as a natural outbreak, effectively staging a fake outbreak event?
https://www.malone.news/p/rsv-vaccine-s ... nals-raise
RSV Vaccine Safety Signals Raise Alarms
Guillain-Barré Syndrome, Preterm Birth, Deaths
Study Design and Method
This retrospective surveillance study assessed 6,790 VAERS reports following RSV vaccination. Researchers conducted descriptive analyses, clinical reviews of serious adverse events (AEs), and empirical Bayesian data mining to identify disproportionate reporting signals. Outcomes of interest included Guillain-Barré Syndrome (GBS), preterm delivery, anaphylaxis, and inappropriate administration during pregnancy.
Findings
Among the post-licensure storm clouds trailing the nation’s first RSV vaccines, a few troubling signals flash like distant lightning. The rare, but serious neurological condition Guillain-Barré Syndrome (GBS) surfaced in 81 reports, 59 of which met rigorous diagnostic criteria. Nearly three-quarters of those affected required hospitalization. One case, following administration of Arexvy, ended in death.
Pregnancy-related complications cast a darker shadow still. Among women who received RSV vaccines during pregnancy—especially Pfizer’s Abrysvo—88 reports of preterm birth emerged, some just days after injection. This signal wasn’t subtle; data analysis flagged the frequency of preterm birth with unusually high strength, suggesting the pattern may be more than coincidence. Ten stillbirths and seven cases of preeclampsia further deepen the concern.
The vaccine safety system also recorded 53 deaths, the majority in elderly recipients (median age: 81). The most common culprits: sudden cardiac arrest, respiratory failure, and GBS. While causality cannot be confirmed from VAERS data alone, the timing and clustering of these events deserve serious attention.
Less deadly but still significant were reports of anaphylaxis—14 confirmed cases of severe allergic reaction, some requiring hospitalization—and 44 cases of cellulitis, mostly mild, occurring at or near the injection site.
In a disquieting administrative twist, 367 pregnant individuals were mistakenly given Arexvy—despite its lack of approval for use during pregnancy. While most of these women reported no adverse outcomes, two suffered serious complications, including one case of hypoxic ischemic encephalopathy, a severe condition affecting the infant’s brain due to oxygen deprivation.
Finally, data mining revealed disproportionately high reporting of serious outcomes—GBS, preterm delivery, stillbirth, premature rupture of membranes—especially among younger recipients of Abrysvo. These are not faint statistical whispers but loud signals requiring immediate vigilance and further study.
In sum, while most reports were non-serious and consistent with prior expectations, this post-market snapshot reveals cracks in the veneer of safety for certain populations. The message is not panic—but precision. For the most vulnerable among us—the pregnant, the elderly, and the immunocompromised—ongoing surveillance may mean the difference between prevention and harm
[url]https://jonfleetwood.substack.com/p/bird-flu-outbreak-follows-vaccination[/url]
[quote]Bird Flu ‘Outbreak’ Follows Vaccination in Same South African City—Was It the Virus or the Vaccine?
Are governments faking disease outbreaks with Trojan Horse vaccines?[/quote]
[quote]Summary
June 6, 2025: South Africa begins mass poultry vaccination using three approved H5 vaccines: Vectormune® H5, Boehringer Ingelheim B.E.S.T H5, and Zoetis HPAI H5N1—all containing detectable viral material.
June 30, 2025: Astral Foods receives permit to vaccinate chickens in Mpumalanga with inactivated H5N2 virus.
July 1, 2025: Bird flu is “detected” in two Mpumalanga poultry farms.
PCR testing is a standard method used by South African veterinary authorities to detect purported avian influenza strains.
All three vaccines registered for use in South Africa contain viral RNA or DNA that can be detected by PCR.
Key question: Did officials detect a genuine H5N1 infection—or simply pick up vaccine-derived RNA and reclassify it as a natural outbreak, effectively staging a fake outbreak event?[/quote]
[url]https://www.malone.news/p/rsv-vaccine-safety-signals-raise[/url]
[quote]RSV Vaccine Safety Signals Raise Alarms
Guillain-Barré Syndrome, Preterm Birth, Deaths[/quote]
[quote]Study Design and Method
This retrospective surveillance study assessed 6,790 VAERS reports following RSV vaccination. Researchers conducted descriptive analyses, clinical reviews of serious adverse events (AEs), and empirical Bayesian data mining to identify disproportionate reporting signals. Outcomes of interest included Guillain-Barré Syndrome (GBS), preterm delivery, anaphylaxis, and inappropriate administration during pregnancy.
Findings
Among the post-licensure storm clouds trailing the nation’s first RSV vaccines, a few troubling signals flash like distant lightning. The rare, but serious neurological condition Guillain-Barré Syndrome (GBS) surfaced in 81 reports, 59 of which met rigorous diagnostic criteria. Nearly three-quarters of those affected required hospitalization. One case, following administration of Arexvy, ended in death.
Pregnancy-related complications cast a darker shadow still. Among women who received RSV vaccines during pregnancy—especially Pfizer’s Abrysvo—88 reports of preterm birth emerged, some just days after injection. This signal wasn’t subtle; data analysis flagged the frequency of preterm birth with unusually high strength, suggesting the pattern may be more than coincidence. Ten stillbirths and seven cases of preeclampsia further deepen the concern.
The vaccine safety system also recorded 53 deaths, the majority in elderly recipients (median age: 81). The most common culprits: sudden cardiac arrest, respiratory failure, and GBS. While causality cannot be confirmed from VAERS data alone, the timing and clustering of these events deserve serious attention.
Less deadly but still significant were reports of anaphylaxis—14 confirmed cases of severe allergic reaction, some requiring hospitalization—and 44 cases of cellulitis, mostly mild, occurring at or near the injection site.
In a disquieting administrative twist, 367 pregnant individuals were mistakenly given Arexvy—despite its lack of approval for use during pregnancy. While most of these women reported no adverse outcomes, two suffered serious complications, including one case of hypoxic ischemic encephalopathy, a severe condition affecting the infant’s brain due to oxygen deprivation.
Finally, data mining revealed disproportionately high reporting of serious outcomes—GBS, preterm delivery, stillbirth, premature rupture of membranes—especially among younger recipients of Abrysvo. These are not faint statistical whispers but loud signals requiring immediate vigilance and further study.
In sum, while most reports were non-serious and consistent with prior expectations, this post-market snapshot reveals cracks in the veneer of safety for certain populations. The message is not panic—but precision. For the most vulnerable among us—the pregnant, the elderly, and the immunocompromised—ongoing surveillance may mean the difference between prevention and harm[/quote]